IRISBOND, founded in 2013, designs and manufactures digital devices equipped with eye-tracking that detect the pupil via infrared light and allow users to control a computer or tablet with their gaze. Its products target people with speech and motor difficulties—including patients with ALS and cerebral palsy—facilitating communication, reading, social interaction and personal development. The company exports roughly 75–80% of its sales to Europe, the U.S. and LATAM and reported a 58% increase in sales in 2022 versus the prior year. Its eye-tracking and Augmentative and Alternative Communication (CAA) solutions were recently included in the Spanish Sistema Nacional de Salud prescription catalogue and are already prescribed in 11 autonomous communities. IRISBOND is also adapting its technology for early diagnosis of neurodegenerative diseases in collaboration with universities and biomedical research centres. A press release dated 27/10/2023 reports that IRISBOND received €2M from several investors. The article names the Sociedad de Capital Riesgo del Grupo SPRI as a participating investor. It also states that the Hazitek Singular program participated in the transaction. The announcement was published on webcapitalriesgo.com. The article does not disclose the financing instrument, valuation, use of proceeds, founding year, location, or operating metrics. No additional investor names or details about past rounds are provided in the text. Irisbond develops an eye-tracking system (eyetracking) that lets users control a computer through eye movement, with primary applications in assisted communication for people with mobility or speech limitations. The company also positions the technology for industrial use cases, collaborative robotics and neuromarketing. Irisbond was founded in 2013 and has built an international distributor network across markets including Spain, Argentina, Chile, Peru, the United States, France, Ireland, Greece, Finland, India and South Africa. Management says the company will pursue an international expansion plan and new disruptive technology developments based on artificial intelligence. To finance that growth, Irisbond closed a fundraising package in 2018 and expects to make further investments to support the expansion and R&D roadmap. Irisbond builds assistive eye-tracking technology for controlling computers. In October 2013 the company launched Irisbond Primma, described as a reliable, intuitive and precise system that controls a PC via eye movement. Irisbond has focused on the disability segment, targeting users with mobility and speech challenges such as ALS, paraplegia and cerebral palsy. The company was founded in 2013 in San Sebastián and counts Vicomtech-IK4 as a technology partner. It has established a distributor network across Spain, Chile, Argentina, the United States, Peru, France, Ireland, Greece, Finland, India and South Africa. In 2015 Irisbond closed a €300,000 funding round to develop its business plan.

Total raised

$5M

Funding rounds

5

Latest round

Debt Financing

Latest activity

May 2024